Alnylam Pharmaceuticals | ALNY - Operating Expenses

Stock Price
330.34
Daily Change
11.49 3.60%
Monthly
2.09%
Yearly
41.81%
Q2 Forecast
309.25

Alnylam Pharmaceuticals reported $965.32M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.8B 23M Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Takeda JPY 1.02T 400.98B Dec/2025
Tectonic Therapeutic USD 21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xencor USD 81.86M 13.35M Dec/2025